What are the main alternatives to Korlym (mifepristone) for Cushing’s syndrome?
Korlym is mifepristone, used for adults with endogenous Cushing’s syndrome who have type 2 diabetes or have glucose intolerance and for whom surgery is not an option or has not been successful (per its labeled indication) [1]. Alternatives depend on what aspect you’re trying to address: tumor control (when possible), lowering cortisol production, or controlling cortisol receptor effects.
If surgery isn’t possible, what drug options are used instead?
When surgery is not an option or has not worked, clinicians typically consider cortisol-lowering medicines and, in some cases, medication that targets cortisol signaling. Common alternatives in the Cushing’s setting include cortisol synthesis inhibitors (to reduce cortisol production) and other agents used to manage hypercortisolism when mifepristone isn’t appropriate [1].
Are there differences vs Korlym in how the medicines work?
Korlym blocks the effects of cortisol at the glucocorticoid receptor. That mechanism can differ from other approaches that aim to reduce how much cortisol the body makes. Because of that, patients may see different patterns in glucose control, symptom changes, and monitoring targets even when they’re being treated for the same underlying syndrome [1].
Can newer “Cushing’s drugs” replace Korlym, or is the choice individualized?
The best alternative is individualized based on:
- Whether surgery is an option
- The patient’s diabetes/glucose intolerance status
- The cause of Cushing’s (e.g., ACTH-dependent vs ACTH-independent)
- Prior treatments and tolerability
- Monitoring needs and drug–drug interactions
Those factors matter because Korlym’s specific labeled use and mechanism are not always interchangeable with other cortisol-lowering strategies [1].
What side effects and safety monitoring do patients compare with Korlym?
Patients often look for alternatives partly to reduce adverse effects or simplify monitoring. Safety and monitoring for Korlym includes checking for blood pressure changes, potassium, and glucose-related outcomes, since blocking glucocorticoid signaling can affect metabolic and electrolyte balance [1]. Alternatives also require monitoring, but the parameters can differ because their mechanisms are different.
What to ask a clinician if you’re searching for a Korlym substitute
If you’re comparing Korlym alternatives, the most useful questions are:
- “Am I a candidate for surgery or repeat surgery, and if not, what non-surgical options fit my subtype?”
- “Would a cortisol synthesis inhibitor or another cortisol-signaling approach be appropriate for my diabetes/glucose intolerance?”
- “What monitoring will I need (glucose, potassium, blood pressure, liver tests) with the alternative you’re proposing?”
- “How would this choice change expected outcomes compared with Korlym?”
These questions map directly to how the alternatives are selected in practice for endogenous Cushing’s syndrome [1].
---
If you tell me what condition you’re treating (endogenous Cushing’s syndrome type, and whether it’s ACTH-dependent or ACTH-independent) and whether you mean “alternatives” as in “other drugs with similar purpose” or “similar dosing/coverage/availability,” I can narrow the options more precisely.
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207685